Vitamin E and its anticancer effects

Area of Science:

• Nutritional biochemistry
• Cancer research
• Molecular biology

Background:

• Vitamin E, a lipid-soluble vitamin, exists as eight isoforms: tocopherols (α, β, δ, γ) and tocotrienols (α, β, δ, γ).
• Early cancer research primarily focused on alpha-tocopherol, but major clinical trials yielded inconclusive results.
• Recent findings suggest a shift towards investigating the anticancer potential of non-alpha tocopherol isoforms.

Purpose of the Study:

• To review the current understanding of vitamin E's anticancer mechanisms.
• To discuss controversies surrounding vitamin E's role in cancer over the past three decades.
• To highlight the need for further clinical research on non-alpha tocopherol isoforms.

Main Methods:

• Literature review of preclinical and clinical studies on vitamin E and cancer.
• Analysis of biochemical and molecular mechanisms of action for different vitamin E isoforms.
• Discussion of results from key clinical trials, including SELECT and ATBC.

Main Results:

• Gamma-tocopherol and delta-tocopherol can neutralize reactive nitrogen and oxygen species.
• Tocotrienols exhibit unique anticancer effects through antiangiogenesis, HMG CoA reductase inhibition, and NF-κB pathway modulation.
• Preclinical data for non-alpha tocopherol isoforms demonstrate promising anticancer activity.

Conclusions:

• The focus in vitamin E cancer research has shifted from alpha-tocopherol to other isoforms due to trial outcomes.
• Non-alpha tocopherol isoforms, particularly tocotrienols, possess distinct and potent anticancer properties.
• Further large-scale clinical studies are warranted to validate the anticancer efficacy of non-alpha tocopherol isoforms.